Open AccessVEGF IN NEOPLASTIC ANGIOGENESIS
Author(s) -
В. П. Чехонин,
Sergey A. Shein,
А. А. Корчагина,
О. И. Гурина
Publication year - 2012
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn.v67i2.119
Subject(s) - angiogenesis , bevacizumab , malignancy , cancer research , medicine , cancer , vascular endothelial growth factor , colorectal cancer , breast cancer , oncology , pathology , vegf receptors , chemotherapy
Solid tumor progression largely depends on vascularization and angiogenesis in the malignant tissue. The most prominent among all proangiogenic factors is vascular endothelium growth factor (VEGF). VEGF suppression leads to retrogression of neoplastic vessels and tumor growth restriction. Clinical trials of complex antiangiogenic and chemical therapy of different neoplastic tumors have shown promising results. Nowadays bevacizumab is widely used in breast cancer, colorectal cancer and II-IV stage of malignancy gliomas treatment. Unfortunately, in the majority of cases antiangiogenic treatment led not to full recovery, but only to tumor development restriction. Resistance mechanisms include potentiating of alternative proangiogenic signaling pathways and activation of malignant cell invasive population.